Prescribing Information - Refer to SPC before prescribing.

Twinrix **Adult and** ***Twinrix*** **Paediatric.** Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed). **Uses**: Active immunisation against hepatitis A and B virus infection. **Dosage and administration:** Three doses (at 0, 1 and 6 months). When necessary due to timing of travel, for more rapid protection in adults (18 years and above), use 0, 7 and 21 days schedule; fourth dose at 12 months. *Adults and adolescents 16 years and abo*ve: 1 ml (720 ELISA HA/20 µg HBsAg) i.m. (deltoid); *Children 1 - 15 years*: 0.5 ml (360 ELISA HA/10 µg HBsAg) i.m (deltoid, or anterolateral thigh in infants). **Contra-indications:** Hypersensitivity to any components, neomycin or hepatitis A or B vaccines. Acute severe febrile illness. **Precautions:** Not recommended for post-exposure prophylaxis. In haemodialysis patients and persons with an impaired immune system, anticipated immune response may not be achieved after the primary immunisation course and may therefore require additional doses of vaccine. Nevertheless, these patients may fail to demonstrate an adequate response. Consider serological testing of subjects at risk of not achieving seroprotection following a complete course of *Twinrix* Adult. Appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event. Avoid intradermal injection or intramuscular administration into gluteal muscle due to suboptimal response. Do not administer intravascularly under any circumstances. Subcutaneous administration may be considered for those with bleeding disorders. **Interactions:** For information on the concomitant use of *Twinrix* Paediatric/Adult with other vaccines please refer to the SPC. Use different injection sites if administering *Twinrix* Adult with other vaccines. **Pregnancy:** Only when clear risk of hepatitis B infection. **Lactation:** Caution in breast feeding. **Adverse reactions**: See SPC for full details. *Common*: appetite loss, headache, injection site reactions, swelling at injection site, fatigue, drowsiness, irritability, GI symptoms, nausea, malaise, fever. *Serious*: anaphylaxis, thrombocytopenia, neurological disorders such as Guillain-Barré syndrome, encephalitis, encephalopathy, convulsions, angioneurotic oedema, meningitis, vasculitis, abnormal liver function tests, multiple sclerosis, optic neuritis. **Legal category:** POM **Presentation and basic NHS cost:** *Twinrix* Adult pre-filled 1.0ml syringe. 1, £33.31; 10, £333.13. 1, £26.44.*Twinrix* Paediatric pre-filled 0.5ml syringe. 1, £20.79. **MA number**: Twinrix Adult: EU/1/96/020/001-003, 007-009. Twinrix Paediatric: EU/1/97/029/001-002, 006-010. **MA holder:** GlaxoSmithKline Biologicals s.a, Rue de l'Institut 89 1330 Rixensart, Belgium. For the UK, further information is available from Customer Contact Centre, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT; customercontactuk@gsk.com; Freephone: 0800 221 441. For Ireland, please contact 1800 244 255. *Twinrix* is a registered trademark of the GlaxoSmithKline group of companies. **Date of preparation:** October 2018. UK/VAC/0075/15(1)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441